CANCERVAX GETS APPROVAL FOR D93

CancerVax has announced that the FDA has approved the company's investigational new drug application for D93, an investigational, humanized, monoclonal antibody with a novel anti-angiogenic and tumor inhibitory mechanism of action.

Preclinical studies with D93 have demonstrated its ability to reduce angiogenesis and inhibit tumor growth in in vivo models of several types of cancer. The company plans to initiate a Phase I clinical trial to evaluate the safety and tolerability of D93 in the treatment of patients with solid tumors later in 2006.